MA30598B1 - Composition pharmaceutique contenant un acide tetrahydrofolique. - Google Patents

Composition pharmaceutique contenant un acide tetrahydrofolique.

Info

Publication number
MA30598B1
MA30598B1 MA31584A MA31584A MA30598B1 MA 30598 B1 MA30598 B1 MA 30598B1 MA 31584 A MA31584 A MA 31584A MA 31584 A MA31584 A MA 31584A MA 30598 B1 MA30598 B1 MA 30598B1
Authority
MA
Morocco
Prior art keywords
tetrahydrofolic acid
pharmaceutical composition
composition containing
progestagen
estrogen
Prior art date
Application number
MA31584A
Other languages
English (en)
Inventor
Kristina King
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36763829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30598(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA30598B1 publication Critical patent/MA30598B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques solides, en particulier des contraceptifs oraux, comprenant un progestagène, telle que la drospirénone; un oestrogène, tel que l'éthinyloestradiol; un acide tétrahydrofolique ou sel pharmaceutiquement acceptable de celui-ci, tel que le 5-méthyl-(6S)- tétrahydrofolate de calcium; et au moins un excipient ou support pharmaceutiquement acceptable. Les compositions de l'invention confèrent une bonne stabilité de l'acide tétrahydrofolique au stockage tout en garantissant encore une libération rapide et fiable de l'¿strogène et du progestagène présents dans la composition.
MA31584A 2006-07-06 2009-01-23 Composition pharmaceutique contenant un acide tetrahydrofolique. MA30598B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06014002 2006-07-06

Publications (1)

Publication Number Publication Date
MA30598B1 true MA30598B1 (fr) 2009-07-01

Family

ID=36763829

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31584A MA30598B1 (fr) 2006-07-06 2009-01-23 Composition pharmaceutique contenant un acide tetrahydrofolique.

Country Status (31)

Country Link
EP (2) EP2422774B1 (fr)
JP (1) JP2009542591A (fr)
KR (2) KR20090033889A (fr)
CN (3) CN101489563A (fr)
AR (2) AR061958A1 (fr)
AU (1) AU2007271449B2 (fr)
BR (1) BRPI0713565B8 (fr)
CA (2) CA2656131C (fr)
CL (1) CL2007001962A1 (fr)
CO (1) CO6150125A2 (fr)
CR (1) CR10549A (fr)
CU (1) CU20090004A7 (fr)
EC (1) ECSP099030A (fr)
ES (1) ES2626838T5 (fr)
GT (1) GT200900001A (fr)
IL (3) IL196027A0 (fr)
MA (1) MA30598B1 (fr)
MX (1) MX2009000079A (fr)
MY (1) MY169516A (fr)
NO (1) NO347567B1 (fr)
NZ (1) NZ573766A (fr)
PE (3) PE20150287A1 (fr)
PH (1) PH12012501774A1 (fr)
RU (2) RU2479306C2 (fr)
SG (1) SG188869A1 (fr)
TN (1) TNSN08543A1 (fr)
TW (2) TWI508730B (fr)
UA (2) UA105078C2 (fr)
UY (1) UY30462A1 (fr)
WO (1) WO2008003432A1 (fr)
ZA (4) ZA200900868B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
UY32836A (es) * 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
MX356702B (es) * 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CN102516247A (zh) * 2010-12-15 2012-06-27 连云港金康医药科技有限公司 A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2383279A1 (fr) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Procédé de préparation d'estetrol
EP2781214A1 (fr) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation de calcium amorphe L-5-méthyltétrahydrofolate (L-5-MTHF-Ca)
EP2878600B1 (fr) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Complexes stables d'un sel de métal alcalino-terreux d'acide N5-méthyl-tétrahydrofolique et un polyol
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
NZ737945A (en) 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
WO2016203044A1 (fr) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Comprimé orodispersible contenant de l'estétrol
CN105030779A (zh) * 2015-07-21 2015-11-11 福格森（武汉）生物科技股份有限公司 一种(6s)-5-甲基四氢叶酸钙口服营养补充剂及其制备方法
CA3178291A1 (fr) 2016-08-05 2018-04-12 Estetra Srl Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
CN107446458A (zh) * 2017-08-04 2017-12-08 合众（佛山）化工有限公司 一种高耐水性的丙烯酸改性聚氨酯杂化树脂水性涂料
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CR20200486A (es) 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
CN110237046B (zh) * 2019-03-29 2021-07-30 福格森（武汉）生物科技股份有限公司 一种l-5-甲基四氢叶酸微囊的制备方法
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
IT202100008834A1 (it) * 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
CN114569567B (zh) * 2021-12-20 2023-03-14 南通联亚药业股份有限公司 一种稳定的双醋炔诺酮炔雌醇复方片及其制备方法
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
CN116036033A (zh) * 2023-01-06 2023-05-02 青岛润昕德生物医药有限公司 一种地屈孕酮片及其生产工艺
IT202300027360A1 (it) * 2023-12-20 2025-06-20 Lesaffre & Cie Formulazioni solide di folati
CN117771389A (zh) * 2023-12-28 2024-03-29 浙江圣达生物药业股份有限公司 L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
FR2676927B1 (fr) * 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
DK0782449T3 (da) 1994-09-22 2003-08-04 Akzo Nobel Nv Fremgangsmåde til fremstilling af doseringsenheder ved vådgranulering
RU2073529C1 (ru) * 1995-05-16 1997-02-20 Центральный научно-исследовательский рентгенорадиологический институт Композиция для эмболизации кровеносных сосудов
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CN1240387C (zh) 1998-04-17 2006-02-08 奥索一麦克尼尔药品公司 含有叶酸的药用组合物及其用途和给药系统
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
EP1598069B1 (fr) * 1999-08-31 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Combinaison pharmaceutique d'éthinylestradiol et de drospirénone comme contraceptif
EE05317B1 (et) * 1999-08-31 2010-08-16 Bayer Schering Pharma Aktiengesellschaft Etinl”stradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina
IL150775A0 (en) 2000-01-18 2003-02-12 Schering Ag Drospirenone for hormone replacement therapy
US6550482B1 (en) * 2000-04-21 2003-04-22 Vascular Control Systems, Inc. Methods for non-permanent occlusion of a uterine artery
US6864774B2 (en) 2000-10-19 2005-03-08 Matsushita Electric Industrial Co., Ltd. Inductance component and method of manufacturing the same
EP1216713A1 (fr) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions de complexes de estrogen-cyclodextrine
EP1216712A1 (fr) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Complexes d'inclusion de drospirenone et de cyclodextrines
US6537569B2 (en) * 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
CA2476940C (fr) * 2002-02-21 2011-11-01 Bayer Intellectual Property Gmbh Compositions pharmaceutiques contenant un ou plusieurs steroides, un ou plusieurs tetrahydrofolates et de la vitamine b12
WO2004039425A1 (fr) * 2002-10-29 2004-05-13 Toray Industries, Inc. Materiau d'embolisation vasculaire
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE112007001600A5 (de) * 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
RU61120U1 (ru) * 2006-10-13 2007-02-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
RU62008U1 (ru) * 2006-10-13 2007-03-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block

Also Published As

Publication number Publication date
MX2009000079A (es) 2009-01-23
HK1131917A1 (en) 2010-02-12
CA2656131A1 (fr) 2008-01-10
NO347567B1 (no) 2024-01-15
CN101484143A (zh) 2009-07-15
NO20090578A (no) 2009-03-09
EP2422774B1 (fr) 2015-08-12
GT200900001A (es) 2009-12-08
CO6150125A2 (es) 2010-04-20
BRPI0713565B1 (pt) 2021-02-02
CR10549A (es) 2009-01-27
IL245355B (en) 2019-05-30
ZA200900868B (en) 2021-05-26
CN101489563A (zh) 2009-07-22
TNSN08543A1 (en) 2010-04-14
AU2007271449A1 (en) 2008-01-10
AR061958A1 (es) 2008-08-10
RU2009103649A (ru) 2010-08-20
CA2656131C (fr) 2015-10-13
BRPI0713565B8 (pt) 2021-05-25
CN102813663A (zh) 2012-12-12
EP2422774A1 (fr) 2012-02-29
ECSP099030A (es) 2009-02-27
RU2624236C2 (ru) 2017-07-03
TW200812593A (en) 2008-03-16
CA2856344C (fr) 2017-02-28
ES2626838T3 (es) 2017-07-26
SG188869A1 (en) 2013-04-30
CL2007001962A1 (es) 2008-01-04
AU2007271449B2 (en) 2013-07-11
BRPI0713565A2 (pt) 2012-03-20
UA105078C2 (uk) 2014-04-10
CN102813663B (zh) 2019-03-22
ZA201808084B (en) 2021-06-30
MY169516A (en) 2019-04-22
AR106561A2 (es) 2018-01-24
KR20130042638A (ko) 2013-04-26
ZA201808083B (en) 2021-06-30
IL196027A0 (en) 2009-09-01
PH12012501774B1 (en) 2015-09-21
KR20090033889A (ko) 2009-04-06
WO2008003432A1 (fr) 2008-01-10
CN101484143B (zh) 2012-07-04
EP2040683B1 (fr) 2017-03-01
CU23902B1 (fr) 2013-06-28
ZA201501673B (en) 2016-02-24
EP2040683A1 (fr) 2009-04-01
TW201538161A (zh) 2015-10-16
IL245355A0 (en) 2016-06-30
CA2856344A1 (fr) 2008-01-10
EP2040683B2 (fr) 2023-08-16
PE20080273A1 (es) 2008-05-16
NZ573766A (en) 2011-05-27
PH12012501774A1 (en) 2015-09-21
UA100228C2 (uk) 2012-12-10
UY30462A1 (es) 2008-02-29
RU2012133154A (ru) 2014-02-10
JP2009542591A (ja) 2009-12-03
ES2626838T5 (es) 2024-03-14
IL224484A (en) 2016-05-31
PE20150287A1 (es) 2015-03-15
PE20120375A1 (es) 2012-05-23
TWI508730B (zh) 2015-11-21
CU20090004A7 (es) 2011-07-11
RU2479306C2 (ru) 2013-04-20
NO20090578L (no) 2009-03-09

Similar Documents

Publication Publication Date Title
MY169516A (en) Pharmaceutical composition containing a tetrahydrofolic acid
EA200600884A1 (ru) Композиции комплексов экстроген-циклодекстрин
PL1750862T3 (pl) Kompozycja farmaceutyczna zawierająca irbesartan
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2005034908A3 (fr) Forme posologique solide comprenant une fibrate et une statine
IL187813A0 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
MX2007012947A (es) Composiciones biomejoradas.
ATE442147T1 (de) Pharmazeutische zubereitung enthaltend drospirenon
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
TNSN08152A1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation
MA30672B1 (fr) Utilisation de derives de l'azabicyclo hexane
BRPI0511036A (pt) formulações de solução farmacêuticas contendo 17-aag
RU2009148985A (ru) Стабилизированные аморфные формы иматиниба мезилата
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
CA2521909A1 (fr) Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
GB2364641A (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
IL141236A0 (en) New oral formulations for 5-ht4 agonists or antagonists
MY118345A (en) Repinotan kit
TW200800931A (en) Novel piperazines as antimalarial agents
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
MXPA05011497A (es) Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
MA30691B1 (fr) Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.
WO1999047172A3 (fr) Compositions pharmaceutiques orales a prendre sans liquides et contenant des composes d'inclusion